Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which antibiotic combo wins against h. pylori? a Head-to-Head test

NCT ID NCT07746934

Disease control Sponsor: University of Medicine and Pharmacy at Ho Chi Minh City Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 05, 2026 · Last updated Aug 06, 2026 · Updated 1 time

Summary

This trial compares two 14-day antibiotic combinations for treating Helicobacter pylori, a common stomach bacteria that can cause ulcers and stomach cancer. One combination uses metronidazole, the other uses a similar drug called tinidazole. The study will see if tinidazole is just as effective at eradicating the infection, while also comparing side effects and tolerability.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Tinidazole-based bismuth quadruple therapy (tinidazole, esomeprazole, tetracycline, bismuth subcitrate) compared to metronidazole-based bismuth quadruple therapy
What this could lead to
If tinidazole works as well as metronidazole, doctors may have another effective option for treating H. pylori infections, potentially with fewer side effects.
What could go wrong
This is a head-to-head comparison, not a new drug discovery. The outcome depends on real-world effectiveness and tolerability, and results may not apply to all populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 600 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18 years or older. * Confirmed Helicobacter pylori infection * Willing and able to provide written informed consent. Exclusion Criteria: * Pregnancy or breastfeeding. * Gastrointestinal malignancy. * Previous H. pylori eradication therapy. * Liver cirrhosis. * Stage IV or V chronic kidney disease. * Previous gastric surgery. * Known allergy to any study medication. * Use of antibiotics within the previous 4 weeks.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Helicobacter pylori infection are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Helicobacter pylori infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Helicobacter pylori infection

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Medicine and Pharmacy at Ho Chi Minh City

    Ho Chi Minh City, Ho Chi Minh, 70000, Vietnam

More trials for these conditions

Other studies related to the condition(s) this trial covers.